Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Jul 31, 2014 1:16pm

164 Views

Post# 22799211

RE:AVALANCHE - AN IPO MODEL FOR RVX OR ZENIETH

Hi Jkj.

Thanks for the post. This would certainly be ideal for one of the Zenith spin offs. I would be thrilled with something like that. Too bad we don't know where Zenith is at. I'm hoping they are on track for a Zenith IPO in the next few months as stated in the Feb 2014 webcast.

On another subject there was an interesting post by Fundamentals6 on July 26 regarding a mete-analysis that had implications re raising HDL. I would really like to hear a perspective on this research from or science posters like biotech and others. It would be very helpful.

GLTA
Toinv

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?